Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 128 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Start date: Oct 21, 2026 to Oct 22, 2026
  2. Start date: Oct 20, 2026 to Oct 21, 2026
  3. Start date: Oct 19, 2026 to Oct 20, 2026
  4. Start date: Oct 18, 2026 to Oct 19, 2026
  5. Start date: Oct 14, 2026 to Oct 18, 2026
Show 9 earlier versionsHide 9 earlier versions
  1. Start date: Oct 13, 2026 to Oct 14, 2026
  2. Start date: Oct 12, 2026 to Oct 13, 2026
  3. Start date: Oct 11, 2026 to Oct 12, 2026
  4. Start date: Oct 8, 2026 to Oct 11, 2026
  5. Start date: Oct 7, 2026 to Oct 8, 2026
  6. Start date: Oct 6, 2026 to Oct 7, 2026
  7. Start date: Oct 5, 2026 to Oct 6, 2026
  8. Start date: Oct 4, 2026 to Oct 5, 2026
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 20, 2026 to Oct 4, 2026
  1. Recruitment opened
    • Start date: Sep 17, 2026 to Sep 20, 2026
    v114
  2. Start date: Sep 16, 2026 to Sep 17, 2026v113
  3. Start date: Sep 15, 2026 to Sep 16, 2026v112
  4. Start date: Sep 14, 2026 to Sep 15, 2026v111
  5. Start date: Sep 10, 2026 to Sep 14, 2026v110
  6. Start date: Sep 9, 2026 to Sep 10, 2026v109
  7. Start date: Sep 8, 2026 to Sep 9, 2026v108
  8. Start date: Sep 7, 2026 to Sep 8, 2026v107
  9. Start date: Sep 6, 2026 to Sep 7, 2026v106
  10. Start date: Sep 3, 2026 to Sep 6, 2026v105
  11. Start date: Sep 2, 2026 to Sep 3, 2026v104
  12. Start date: Sep 1, 2026 to Sep 2, 2026v103
  13. Start date: Aug 31, 2026 to Sep 1, 2026v102
  14. Start date: Aug 30, 2026 to Aug 31, 2026v101
  15. Start date: Aug 27, 2026 to Aug 30, 2026v100
  16. Start date: Aug 26, 2026 to Aug 27, 2026v99
  17. Start date: Aug 25, 2026 to Aug 26, 2026v98
  18. Start date: Aug 24, 2026 to Aug 25, 2026v97
  19. Start date: Aug 23, 2026 to Aug 24, 2026v96
  20. Start date: Aug 20, 2026 to Aug 23, 2026v95
  21. Start date: Aug 19, 2026 to Aug 20, 2026v94
  22. Start date: Aug 18, 2026 to Aug 19, 2026v93
  23. Start date: Aug 17, 2026 to Aug 18, 2026v92
  24. Start date: Aug 16, 2026 to Aug 17, 2026v91
  25. Start date: Aug 13, 2026 to Aug 16, 2026v90
  26. Start date: Aug 12, 2026 to Aug 13, 2026v89
  27. Start date: Aug 11, 2026 to Aug 12, 2026v88
  28. Start date: Aug 10, 2026 to Aug 11, 2026v87
  29. Start date: Aug 7, 2026 to Aug 10, 2026v86
  30. Start date: Aug 6, 2026 to Aug 7, 2026v85
  31. Start date: Aug 5, 2026 to Aug 6, 2026v84
  32. Start date: Aug 4, 2026 to Aug 5, 2026v83
  33. Start date: Aug 3, 2026 to Aug 4, 2026v82
  34. Start date: Aug 2, 2026 to Aug 3, 2026v81
  35. Start date: Jul 30, 2026 to Aug 2, 2026v80
  36. Start date: Jul 29, 2026 to Jul 30, 2026v79
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cells. Researchers can modify a person s own T cells, or immune cells, to target B7-H3. When these modified T cells are returned to the body-a treatment called B7-H3 chimeric antigen receptor (CAR) T cell therapy-they may help kill cancer cells. Objective: To test B7-H3 CAR T cell therapy in people with SCLC or EPNEC. Eligibility: People aged 18 years and older with SCLC or EPNEC that either did not respond or returned after treatment. Design: Participants will be screened. They will have blood tests and tests of their heart function. They will have imaging scans. Participants will undergo apheresis: Blood will be taken from the body through a needle. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different needle. The collected T cells will be altered to make them attack cells with B7-H3. Participants will be in the hospital for at least 15 days. They will receive chemotherapy drugs to prepare their body for the treatment. These drugs will be given through a tube attached to a needle inserted into a vein. The modified T cells will be infused through a vein. Participants will remain in the hospital until they are well enough to go home. Follow-up visits will continue for 15 years....
Trial Details
NCT Number NCT07509034
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Refractory Small Cell Lung Cancer, Extrapulmonary Small Cell Carcinoma, Neuroendocrine Carcinoma, Poorly Differentiated Neuroendocrine Carcinoma +1 more
Related terms Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov